From the Cosmetic Dermatology Archives

Fixed-Combination Therapy for Moderate to Severe Acne: A Review of Clindamycin Phosphate 1.2%-Benzoyl Peroxide 2.5% Gel

Fixed-combination products are commonly used in the treatment of acne, particularly the combination of clindamycin and benzoyl peroxide (BPO). Benzoyl peroxide is known to cause dryness and irrita­tion, often limiting its use. The potential discomfort that can result from the concentration-dependent tolerability of BPO has only recently been elucidated and is particularly noteworthy. An optimized formulation of clindamycin phosphate 1.2%–BPO 2.5% is highly effective and well-tolerated in the treatment of moderate to severe acne and in adolescent acne. Objective clinical assessments such as lesion counts and physician grading classifications alone do not adequately capture the impact of acne severity from a patient’s perspective; therefore, assessment of patient satisfaction and improvement in quality of life (QOL) are essential. This review provides an analysis of some of the most recent stud­ies on clindamycin phosphate 1.2%–BPO 2.5% gel for the treatment of moderate to severe acne


 

Recommended Reading

Blog: Treating Acne, PIH in Dark Skinned Patients
MDedge Dermatology
Blog: Is Your Phone Smart Enough to Cure Acne?
MDedge Dermatology
Overweight Female Teens More Likely to Have Acne
MDedge Dermatology
Autologous Cells Improve Acne Scarring
MDedge Dermatology
Noninflammatory Acne Lesions Scar, Too
MDedge Dermatology
Acne Oral Antibiotics May Triple Pharyngitis Risk
MDedge Dermatology
Erratum (2007;80:113-120)
MDedge Dermatology
Acne: New Concepts [editorial]
MDedge Dermatology
Evaluating Cosmetic Outcomes and Patient Compliance When Selecting Therapies for Acne Vulgaris
MDedge Dermatology
Fractional Lasers for Acne Scarring in Patients With Skin of Color
MDedge Dermatology